Its neuroprotective and regenerative properties have been demonstrated in AIS models, and an early-phase study using human recombinant G-CSF to mobilize CD34+ cells showed promising results without systemic adverse effects [360]. The gene discussed is CSF3; the disease is androgen insensitivity syndrome.